Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (LCTX)
:LCTX
LCTX Stock Chart & Stats
$1.95
-$0.04(-6.64%)
At close: 4:00 PM EST
$1.95
-$0.04(-6.64%)
Day’s Range― - ―
52-Week Range$0.37 - $2.09
Previous CloseN/A
Volume522.43K
Average Volume (3M)1.04M
Market Cap
$449.14M
Enterprise Value$413.60M
Total Cash (Recent Filing)$40.49M
Total Debt (Recent Filing)$2.62M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Mar 05, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding230,327,530
10 Day Avg. Volume865,844
30 Day Avg. Volume1,043,848
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.28
Price to Sales (P/S)10.59
P/FCF Ratio-4.25
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue38.24
Enterprise Value/Gross Profit39.09
Enterprise Value/Ebitda-9.06
Forecast
1Y Price Target
$9.00Price Target Upside361.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$26.23M
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressExpansion of the Phase 2a delivery optimization study to multiple sites and reported meaningful patient improvements support accelerating clinical momentum and strengthen confidence in future efficacy readouts.
Gene-edited Cell AssetsReceipt of a hypoimmune gene-edited induced pluripotent stem cell line enables development of off-the-shelf cell therapies that could reach patients without immune matching, expanding potential market opportunities.
Partner Validation And FundingA milestone payment from the global partner and the partner's testing of improved delivery devices, together with regulatory designation for the program, signal partner commitment and help validate commercial prospects.
Bears Say
Data Transparency RiskLimited visibility into partner-held clinical data creates uncertainty around program timelines and the likelihood of regulatory and commercial success, increasing execution risk.
Lineage Therap News
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $0.36 and its highest was $2.09 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is $449.14M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Mar 05, 2026 which is tomorrow.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.026 by -$0.104.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 230,327,530 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.026. Following the earnings report the stock price went up 1.734%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LCTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lineage Therap Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (361.54% Upside)
$9.00 (361.54% Upside)
Blogger Sentiment
Bullish
LCTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 25.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
247.59%
12-Months-Change
Fundamentals
Return on Equity
-153.37%
Trailing 12-Months
Asset Growth
-7.20%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
LCTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While Lineage has made significant progress with its OpRegen program and secured important partnerships, financial challenges persist with a decrease in revenue and a significant net loss. The advancements in clinical trials and partnerships offer promising long-term potential, but financial metrics present short-term challenges.View all LCTX earnings summariesLCTX Stock 12 Month Forecast
Average Price Target
$9.00
▲(361.54% Upside)
Technical Analysis
Amarin
―
Tvardi Therapeutics
―
DBV Technologies SA - American
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―
Ownership Overview
15.12% Insiders
4.64% Mutual Funds
1.04% Other Institutional Investors
74.89% Public Companies and
Individual Investors